Short Interest in Pulse Biosciences, Inc. (NASDAQ:PLSE) Decreases By 14.4%

Pulse Biosciences, Inc. (NASDAQ:PLSE) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 2,430,000 shares, a decline of 14.4% from the May 31st total of 2,840,000 shares. Based on an average daily volume of 220,500 shares, the short-interest ratio is presently 11.0 days. Approximately 14.9% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, June 27th.

Insider Activity at Pulse Biosciences

In other news, CEO Burke Thomas Barrett bought 10,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was purchased at an average price of $8.56 per share, with a total value of $85,600.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 71.50% of the stock is owned by company insiders.

Institutional Trading of Pulse Biosciences

Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its stake in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after buying an additional 2,952 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences during the first quarter worth about $88,000. Inspire Investing LLC lifted its position in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after purchasing an additional 10,039 shares in the last quarter. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences during the first quarter worth approximately $109,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences during the fourth quarter worth approximately $242,000. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Price Performance

Pulse Biosciences stock opened at $10.83 on Tuesday. The firm has a fifty day moving average price of $10.14 and a two-hundred day moving average price of $9.56. Pulse Biosciences has a fifty-two week low of $3.78 and a fifty-two week high of $14.96.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Tuesday, May 7th. The company reported ($0.17) earnings per share for the quarter.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.